Intravitreal Bevacizumab (Avastin) therapy for Proliferative Diabetic Retinopathy
Not Applicable
- Conditions
- diabetic retinopathy.Retinal disorders in diseases classified elsewhere
- Registration Number
- IRCT138903314232N1
- Lead Sponsor
- Vice chancellor for research; Babol university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Patients were not offered treatment if they had uncontrolled hypertension or recent myocardial infarction or cerebral vascular accident.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Visual Acuity. Timepoint: 0, 4, 12 weeks. Method of measurement: complete ophtalmic examination.
- Secondary Outcome Measures
Name Time Method Speed of improvement and durability of visual acuity. Timepoint: 4 and 12 weeks after intervention. Method of measurement: ophtalmic examination.